Page 1202 - Basic _ Clinical Pharmacology ( PDFDrive )

1188 Index

Angiotensin, 300–303 Antagonism magnesium, 247, 251t
biosynthesis of, 300–303, 302f in antimicrobial drug, 912–913 potassium, 247, 251t
angiotensin I in, 302f, 302–303 chemical, 25 ranolazine, 247
converting enzyme in, 303 neutral, 6 preparations available, 251t
renin in, 300–301 physiologic, 25–26 sodium channel-blocking drugs, class 1,
renin release in, control of, 301–302, Antagonist. See also specific types 237–243, 239t, 240t, 251t
302f chemical, 3 class 1A
renin-angiotensin system inhibition by, competitive, 23f, 23–24 disopyramide, 239t, 240t,
304–305 definition of, 3, 20–21 240–241, 250t
on renin release, 301 irreversible, 23f, 24 procainamide, 237–239, 239t,
Angiotensin antagonists, 224t noncompetitive, 23f, 24 240t, 250t
Angiotensin-converting enzyme (ACE), pharmacologic, 5, 6f quinidine, 239t, 240, 240t, 250t
303 Antagonist-precipitated withdrawal, 565 class 1B
Angiotensin-converting enzyme inhibitors Anterior pituitary hormones, 668–680, lidocaine, 239t, 240t, 241f,
(ACEIs). See also specific types 682t–684t. See also Pituitary 241–242, 250t
heart failure treated with, 212, 220, hormones, anterior mexiletine, 239t, 240t, 242, 250t
224t, 227 Anthelmintic drugs, 938–947 class 1C
chronic, 222 Anthracyclines, 962t, 964–965 flecainide, 239t, 240t, 242, 251t
preparations available, 226t Anthraquinone derivative laxatives, 1099 moricizine, 243, 251t
hypertension treated with, 179t, Antiandrogens, 743–745, 745t propafenone, 239t, 240t, 242–243,
187–189, 192t, 193t receptor inhibitors, 744f, 744–745, 251t
immediate effects of, 48–49, 49f 745t Antiatherogenesis, nitric oxide for,
preparations available, 193t steroid precursor conversion to andro- 342–343, 343f
on renin-angiotensin system, 304–305 gens in, inhibitors of, 743–744, Antibacterial agents, topical dermatologic
on vasoactive peptides, 316t 744f, 745t acne treated with
Angiotensin I, 302f, 302–303 steroid synthesis inhibitors, 743, 744f, clindamycin, 1071
Angiotensin II 745t dapsone, 1072
on adrenal cortex and kidney, 303 Antiarrhythmic agents, 236–252. See also erythromycin, 1071
on blood pressure, 175, 303 specific agents metronidazole, 1071
on cell growth, 304 action potential-prolonging drugs sodium sulfacetamide, 1071–1072
on central nervous system, 304 (class 3), 243–245, 251t bacitracin and gramicidin, 1070
Angiotensin II inhibitors, for hypertension, amiodarone, 239t, 240t, 243–245, fundamentals of, 1070
187–189 251t mupirocin, 1070
Angiotensin inhibitors, 176, 187–189 dofetilide, 239t, 240t, 245, 251t neomycin and gentamicin, 1071
angiotensin-converting enzyme inhibitors, dronedarone, 239t, 240t, 244, 251t polymyxin B sulfate, 1070–1071
179t, 187–189, 192t–193t ibutilide, 239t, 240t, 245, 251t retapamulin, 1070
angiotensin receptor blockers, 179t, 189, sotalol, 239t, 240t, 244–245, 251t Antibiotic resistance, 793
192t, 193t, 304–305 beta-adrenoceptor-blocking drugs Antibiotics, 793. See also Antimicrobial
mechanisms and sites of action of, 187, (class 2), 243, 251t agents; specific antibiotic
188f calcium channel-blocking drugs (class 4), antitumor
Angiotensin receptor, 304 245–246, 251t anthracyclines, 962t, 964–965
Angiotensin receptor blockers (ARBs) diltiazem, 239t, 240t, 246, 251t bleomycin, 962t, 965–966
heart failure treated with, 220, 224t verapamil, 239t, 240t, 245–246, mitomycin, 962t, 965
chronic, 222 251t malaria treated with
preparations available, 226t chloride channel drugs, 248 clindamycin, 928
hypertension treated with, 179t, 189, classification and overview of, 237, 239t, doxycycline, 920t, 927–928
192t–193t 250t–251t spiramycin, 928
on renin-angiotensin system, 304–305 clinical use of Antibodies
on vasoactive peptides, 316t atrial fibrillation, 249b description of, 979, 980, 982f
Anidulafungin, 859, 861t benefits and risks in, 249 immunosuppressive, 990–991
Anion inhibitors, thyroid, 695 conduct of therapy in, 249 antilymphocyte and antithymocyte,
Anion overdose, 263 pretreatment evaluation in, 248–249 990
Anistreplase, 611f in elderly, 1064 chimeric molecules, 990
Anorgasmia, 547 mechanisms of action of, 233f, 236–239, development of, 990
Antacids 238f hyperimmune immunoglobulins, 991
drug interactions of, 1157t miscellaneous immune globulin intravenous,
OTC, 1123t adenosine, 239t, 240t, 246–247, 251t 990–991
preparations available, 1117t ivabradine, 247 Rh 0 (D) immune globulin, 991